Abstract: The invention is related to particle induced radiography system, comprising a particle radiation source device, implant module, external detector device, central module and other controls, in which the implant module comprises active and/or passive components in tandem with the readout electronics and communication chosen to measure the beam properties and to generate and detect secondary gamma photons from the nuclear interactions, the external detector device provides a position sensitive gamma detector with a high detection efficiency, good spatial resolution and a relatively large field of view necessary for particle treatments useful in monitoring both the implanted device and the patient anatomical areas under treatment, and the external detector device can also be used to perform 3D spectral imaging on any material samples using proton beam as a probe.

Abstract: This system and method of for providing a tunable orbital angular momentum system for providing higher order Bessel beams comprising: an acousto-optical deflector configured to receive an input beam, deflect a first portion of the input beam a first deflection angle relative to an axis of propagation and along an optical axis and deflect a second portion of the input beam a second deflection angle relative to the optical axis; a line generator disposed along the optical angle for receiving the first portion and the second portion of the input beam and provide an elliptical Gaussian mean; a log-polar optics assembly disposed along the optical angle for receiving the elliptical Gaussian beam and wrapping the elliptical Gaussian beam with an asymmetric ring; and, a Fourier lens configured to receive the wrapped elliptical Gaussian beam.

Abstract: A system or method for compressing continuous glucose monitor (CGM) data for a subject and/or a technician, clinician, or for use with an interventional device. The system or method configures the CGM data to allow the subject, technician, clinician, or interventional device to take a physical action in response to receiving a transmission to improve the safety and/or efficacy of therapy for the subject.

Abstract: The present invention provides methods and compositions for treatment of prion disease.

Abstract: The purpose of the present invention is to provide a novel medical application using pluripotent stem cells in regenerative medicine. The present invention provides a cell formulation and pharmaceutical composition that are for amelioration and therapy for frequent urination and bladder pain caused by the inflammation of the bladder and that contain SSEA-3 positive pluripotent stem cells isolated from cultured mesenchymal cells or a mesenchymal tissue of a living organism. The cell formulation according to the present invention is considered to be based on a mechanism in which, for example, Muse cells are administered against interstitial cystitis having the abovementioned disorders to be successfully engrafted into affected bladder tissue, whereby the disorders are ameliorated and treated.

Abstract: Methods of treatment based on a prognosis as determined utilizing a Bayesian framework are provided. Clinical data is utilized within a Bayesian framework to obtain a prognosis of a medical disorder. A prognosis can be updated utilizing a Bayesian framework when subsequent clinical data is acquired, such as clinical data acquired during a treatment or clinical monitoring.

Abstract: Disclosed are a rolled (FeCoNiCrRn/Al)-2024Al composite panel and a preparation method therefor. The preparation method involves taking pure aluminum as a matrix, adding an FeCoNiCrRn medium-entropy alloy with a high strength and toughness as an reinforcing phase to prepare an FeCoNiCrRn/Al composite material, then laminating the FeCoNiCrRn/Al composite material with aluminum alloy 2024, and preparing the (FeCoNiCrRn/Al)-2024Al composite board by means of hot-rolling recombination, which solves the problem that high-strength aluminum matrix composites (AMCs) are prone to instantaneous breakability and low ductility, thereby improving the overall performance of the material. The present disclosure adopts microwave sintering (MWS) to fabricate a medium-entropy alloy-reinforced AMC, and adopts hot-roll bonding to fabricate the (FeCoNiCrRn/Al)-2024Al metal composite panel.

Abstract: A method for detecting at least one systemic condition and at least one locoproximal condition within a surgical site of a subject following a surgery is disclosed. The method includes obtaining a surgical drainage fluid sample from the surgical site and a blood sample from the subject, isolating analyte-containing portions from the surgical drainage fluid sample and the blood sample, and detecting and quantifying at least a portion of the analytes within the analyte-containing portions to produce at least one assay result, wherein the at least one assay result is indicative of the at least one systemic condition and the at least one locoproximal condition within a surgical site of a subject. At least one assay result may be provided to a practitioner and used to select at least one additional treatment.

Abstract: Disclosed herein are inventive methods of making thin films, inventive thin films, and inventive articles and systems comprising thin films. Certain embodiments are related to methods of making thin films in which reagents are arranged within a first phase and a second phase such that at least one reagent reacts to form a thin film proximate to the interface between the first phase and the second phase. Thin films (including two-dimensional materials) disclosed herein can have one or more of a variety of beneficial properties including large lateral dimension(s), lateral continuity, high mechanical strength, consistent spatial composition, and/or consistent thickness. In accordance with certain embodiments, thin films disclosed herein can be combined to form a variety of inventive multi-layer articles, including multi-layer articles comprising a combination of thin films having different compositions that interact with each other via van der Waals forces.

Abstract: An antimicrobial composition containing a synergistic combination of an imidazole antifungal agent and activated creatinine is provided, wherein the imidazole antifungal agent represents in the range of about 0.5 mol % to about 30 mol % of the combination of the antifungal agent and the activated creatinine in the composition. Methods for treating bacterial infections, fungal infections, viral infections, and wounds are also provided, as are other methods of use, including methods for disinfecting inert surfaces, methods for preserving food products, and methods for treating plants. In addition, the invention provides a method for enhancing the antifungal effect of an imidazole antifungal agent as well as a method for enhancing the antibacterial effect of activated creatinine. Compositions and methods involving use of activated 2-amino-imidazol-4-one analogs other than activated creatinine are also provided.

Abstract: Provided herein are methods of treating a dysmyelinating/demyelinating disease or condition in a patient in need thereof. The methods comprise restoring Qki-PPAR?-RXR?-dependent lipid metabolism in myelin. For example, the methods comprise administering a PPAR? agonist or an RXR agonist to the patient.

Abstract: The present application discloses a human-computer interaction method and an interaction system based on capacitive buttons. The method comprises the following steps: acquiring a capacitive charging signal generated by a user finger-touching a capacitive button; processing the capacitive charging signal to extract Mel-frequency cepstrum coefficient characteristics; and inputting the Mel-frequency cepstrum coefficient characteristics into a trained hidden Markov model, identifying a finger type of the user touching the capacitive button, and further implementing human-computer interaction according to an identification result.

Abstract: A method and a system for managing voting of an alliance chain based on variable strategies are provided. The method specifically includes: 1) classifying channel strategies into an implicit strategy and a strategy based on signature; 2) specifically implementing the variable strategies: initiating, by a user, a proposal request for modifying a strategy; detecting whether a content of the strategy meets a format requirement on the condition that a target strategy is a strategy based on signature; sending a voting invitation or a signature invitation to an organization requiring auditing according to a present channel strategy or a present network strategy; voting or signing by the invited organization; analyzing a result to determine whether the result meets a requirement of the present channel strategy; if so, modifying the present channel strategy to a target channel strategy; otherwise, failing in modification.

Abstract: Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjutant.

Abstract: A computational model may be used to predict targets of a candidate, or predict candidates that interact with a target. A plurality of pairs may be established, each including a candidate and a respective one of a plurality of controls, each of the plurality of controls known to bind with a target. For each pair, values of at least two datatypes of the candidate may be compared to values of the at least two datatypes of the respective one of the plurality of controls in the pair to generate a similarity score for each of the at least two datatypes of each pair. Similarity scores may be converted to likelihood values indicating likelihood that the candidate and the controls have a shared target based on the respective one of the at least two datatypes. Tests may be performed to validate predictions regarding interactivity of candidates and targets.

Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein R1-R6 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as contraceptive agents.

Abstract: A method for treating a cancer of similar or same histological type is provided. The method includes administering a xenogeneic tissue cell composition to a subject in need for a treatment of the cancer of similar or same histological type. The xenogeneic tissue cell composition does not include a tumor cell, and the xenogeneic tissue cell composition is administered to the cancer of the similar or same histological type by an intralesional route.

Abstract: Disclosed are a system and a method for measuring a magnetorefractive effect of an optical fiber. The system comprises a laser, a coupler A, a sensing optical fiber, a reference optical fiber, a carrier generator, a coupler B, a photoelectric detector and a data acquisition and processing module. The coupler A, the sensing optical fiber, the reference optical fiber and the coupler B form a Mach-Zehnder optical fiber interferometer. An external magnetic field influences the refractive index of the sensing optical fiber, so that the optical path difference between two paths of optical signals in the sensing optical fiber and the reference optical fiber is changed, the intensity of an interference optical signal output by the coupler B is changed, and the refractive index change of the sensing optical fiber under the action of the magnetic field is measured by detecting and processing the interference optical intensity.

Abstract: Provided are a heat dissipation structure and a heat dissipation system. The heat dissipation structure includes a heat dissipation channel and a plurality of heat dissipation fins. The plurality of heat dissipation fins are arranged on at least one side of the heat dissipation channel. Heat dissipation fins arranged on the same side of the heat dissipation channel are arranged along an extension direction of the heat dissipation channel. The heat dissipation channel and the plurality of heat dissipation fins are each formed as a cavity structure. Each heat dissipation fin includes a first end and a second end arranged opposite to each other. The first end is a closed end, and the second end is an open end. The second end communicates with the heat dissipation channel.

Abstract: The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.